Project Grant R41GM165098
Award Date 9/12/25
Completion Date 8/31/26
Dollars Obligated $350K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Institute of General Medical Sciences (NIGMS) awarded a $298,530 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Epigenter, LLC in Providence, RI. The grant supports the development of "Epigenetic Editor Therapeutics" - a novel approach to modulating gene expression without altering the DNA sequence. The project aims to create recombinant, self-delivering epigenetic editor proteins that can be taken up by cells and targeted to...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $650,079 Project Grant to Northeastern University under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports the development and optimization of novel small-molecule probes targeting the alpha9 nicotinic acetylcholine receptor (α9*-nAChR) subunit, with the goal of exploring its potential for pain management. The 5-year project aims to advance...
- The National Institute of General Medical Sciences (NIGMS) awarded Epicypher, Inc. a $1,264,176 project grant under the Biomedical Research and Research Training federal grant program (CFDA 93.859) to develop a novel toolbox for studying how asymmetric post-translational modifications (PTMs) on nucleosomes regulate chromatin biology. The key products and services to be delivered include: A novel manufacturing method to efficiently generate asymmetric designer nucleosomes (A-dNucs) at...
- This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...
- The National Institute of General Medical Sciences (NIGMS) awarded a $218,622 Project Grant to Vitan-Biotech LLC on September 22, 2023 under the Biomedical Research and Research Training program (CFDA 93.859). The grant will fund the development of an integrated pipeline to rapidly discover and characterize selective, high-affinity nanobodies against defined G protein-coupled receptors (GPCRs) that are important for neurological disorders like schizophrenia, pain, Parkinson's, Alzheimer's, and...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $400,000 Project Grant to Navega Therapeutics, Inc., a San Diego-based biotechnology company, under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding will support Navega's research and development efforts to advance novel epigenetic gene therapies targeting the voltage-gated sodium channel NAV1.7 for the treatment of chronic pain. This innovative approach aims to transiently repress NAV1.7...
- This federal Project Grant award of $350,000, provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), is funding the development of allosteric uncouplers as potential therapeutics for chronic pain. The primary goals are to create safe, non-opioid alternatives to address the ongoing opioid crisis, which has led to nearly 100,000 overdose deaths in the U.S. in 2021 alone. The grant recipient, Unco...
- This $4,039,366 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), will support a research project titled "A Fully Humanized Functional Genomic Screen to Identify and Validate Pain Therapeutic Targets" under the NIH's Drug Use and Addiction Research Programs (CFDA 93.279). The project will leverage innovative CRISPR-based screening and human dorsal root ganglion (DRG) transcriptomic data to...
- This Project Grant award of $371,871 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), will fund a biopsychosocial investigation into contemporary human models of postoperative pain. The project aims to gain a deeper understanding of the mechanisms underlying nociception and the pain experience in surgical patients. Key activities include examining endogenous pain modulation, pain neurocircuitry,...
- This federal Project Grant award of $118,457.00 from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), is funded under the Drug Use and Addiction Research Programs (CFDA 93.279). The award supports research by Dr. Sylvanus Toikumo at the University of Pennsylvania to characterize the genetic architecture underlying chronic pain and addiction, with the goal of informing the development of non-addictive analgesic medications. The project aims to leverage...